Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis
References (19)
- et al.
Mortality among arthritics
J Chron Dis
(1976) Leukemia or lymphoma occurring subsequent to an autoimmune disease
Blood
(1967)- et al.
Interpreting the biological significance of rheumatoid factor
Ann Rheum Dis
(1975) Postmortem findings and articular pathology in rheumatoid arthritis
Cancer and arthritis
Arthritis Rheum
(1967)- et al.
Malignancy in a series of 70 patients with systemic lupus erythematosus
Arthritis Rheum
(1974) - et al.
Length of life and cause of death in rheumatoid arthritis
New Engl J Med
(1953) - et al.
Confidence limits on the ratio of two Poisson variables
Am J Epid
(1974) - et al.
Mortality in systemic lupus erythematosus: a 10-year review
Brit Med J
(1973)
There are more references available in the full text version of this article.
Cited by (407)
Cross talks between autoimmunity and cancer
2022, Translational Autoimmunity: Autoimmune Disease Associated with Different Clinical FeaturesCancer and Rheumatoid Arthritis
2020, Rheumatic Disease Clinics of North AmericaCancer risk and tumour necrosis factor inhibitors in patients with inflammatory arthritis
2020, Pharmacological ResearchReal world data in rheumatology
2019, Seminars in Arthritis and RheumatismMyeloid disorders after autoimmune disease
2019, Best Practice and Research: Clinical HaematologyCitation Excerpt :Several early case reports and case series have reported on the association between AML/MDS and RA, among patients exposed to azathioprine [68], methotrexate [121], cyclophosphamide [122], anti-TNF agents [123]. This excess leukemia risk was further confirmed in several population-based cancer registry studies [101,124–126]. A few controlled studies have specifically evaluated DMARD use and risk of hematologic malignant neoplasms, and found a significant, albeit weak, association with azathioprine and cyclophosphamide therapies [127–129].
Copyright © 1978 Published by Elsevier Inc.